Imaging of Type 1 Diabetes Progression

Status unconfirmed

Conditions studied: Type 1 Diabetes

In brief

Type 1 diabetes results from the autoimmune destruction of the insulin-producing beta cells of the islets of Langerhans of the pancreas. Initially, diabetes is usually clinically silent with immune cells invading the pancreatic islets, a process termed insulitis, which eventually leads to loss of beta cells in the islets. If enough beta cells are destroyed, the body can not make enough insulin to maintain blood sugars in the normal range and clinical diabetes develops. The purpose of this study is to assess the ability of magnetic resonance imaging with ferumoxytol to detect changes in the pancreas associated with the insulitis of type 1 diabetes.

Key facts

Study ID

NCT01521520

Run by

Jason Gaglia

People needed

65

Starts

2012-01-01

Last updated by the study team

2017-04-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participation in a collaborating diabetes clinical trial
• Able to understand written consent document and HIPAA authorization prior to initiation of study related procedures and are willing to participate

You may not qualify if…

• Known allergy to ferumoxytol or iron
• Individuals who are pregnant or lactating
• Iron saturation above the upper limit of normal
• Individuals with a counter-indication to MRI, such as the presence of metallic prostheses or implanted metal device (e.g., infusion pump, defibrillator)
• Individuals with known clinical conditions that may lead to iron overload including hemochromatosis, cirrhosis, or sickle cell disease

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.